Megestrol Kabi (Megestrol Acetate)

Megestrol acetate acts as a synthetic progestogen that binds to progesterone receptors, producing antigonadotropic effects that lower gonadotropin secretion. Its glucocorticoid‑like activity influences metabolism, increasing appetite and promoting protein synthesis, while also exerting anti‑proliferative effects on hormone‑sensitive cancer cells.

The dosage of Megestrol Kabi is individualized and determined by the prescribing clinician based on the patient’s condition, severity, and response to therapy. Healthcare providers consider factors such as weight loss severity, cancer type, and overall health when setting the appropriate dose.

Safety of Megestrol Kabi in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternatives with their healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifying trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Megestrol Kabi is a progestin with both appetite‑stimulating and hormone‑modulating properties, distinguishing it from other agents such as megestrol acetate’s alternative, dronabinol, which acts on cannabinoid receptors. Megestrol offers additional anti‑tumor activity in hormone‑responsive cancers, whereas many other stimulants lack this dual function.

Megestrol Kabi should be stored at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability throughout its shelf life.

Megestrol Kabi is taken orally, usually as a tablet or capsule, with or without food as directed by the prescribing clinician. The exact administration schedule, including timing and whether it should be taken with meals, is determined by the healthcare provider based on individual patient needs.

Serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, adrenal suppression leading to cortisol deficiency, severe hyperglycemia, and significant liver dysfunction. Patients should be monitored closely for signs of these conditions, and therapy should be discontinued if serious adverse events occur.

Megestrol Kabi is contraindicated in patients with known hypersensitivity to megesterol acetate or any excipients, those with uncontrolled hypertension, active thromboembolic disease, or severe liver impairment. It should also be avoided in individuals who are pregnant unless the benefits outweigh the risks, and in patients with uncontrolled diabetes without proper monitoring.